NCT00198120.

Study name	Safety and effectiveness of D‐cycloserine in children with autism
Methods	8‐week parallel trial of D‐cycloserine versus placebo
Participants	Inclusion criteria: aged 3‐12 years clinical diagnosis of autism based on DSM‐IV ABC‐lethargy subscale of ≥ 13 Exclusion criteria: severe or profound intellectual disability weight < 11 kg other neurodevelopmental disorders any psychiatric disorders requiring treatment significant renal, hepatic, or cardiovascular disorders Setting/location: assumed to be in the USA Sample size: target sample size is 80
Interventions	Intervention (D‐Cycloserine) for 8 weeks: maximum 1.7 mg/kg/day Comparator (placebo) for 8 weeks: equivalent placebo
Outcomes	No relevant outcomes
Starting date	Trial registry last updated 2016
Contact information	Name: Christopher J McDougle Contact details: not provided
Notes	Source of funding: Indiana University Conflicts of interest: unclear